New York, USA – October 19, 2021 – DDA platform, the mature division of Creative Bioarray, is an innovative biotechnology company whose mission focuses on developing cutting-edge products and high quality services to support research in the field of the pharmaceutical, biotechnology, agricultural, and diagnostics industries. DDA platform is always devoted to accelerating life science research, solving complex analytical challenges, and increasing laboratory productivity. Recently, it announced the release of its professional DMPK services which can be applied to accelerate early discovery stage of drug development.
DMPK studies and absorption, distribution, metabolism, excretion, and toxicity analysis (ADMET) are the basis for optimizing compounds in order to assess bioavailability, drug interaction (DDI) and related risks. The evaluation of DMPK can minimize the wastage rate of candidate drugs and improve the efficiency of overall drug discovery. Another benefit of DMPK research in the drug discovery and development process is that it allows chemists and analysts to achieve reasonable structural modifications, thereby improving the pharmacokinetic properties and efficacy of drugs.
In Creative Bioarray, a dedicated DMPK department provides high-quality services and a wide range of standard in vitro and in vivo testing, covering the early detection stage and more advanced compound analysis. PK/PD analysis is usually performed at every stage of the drug development process. Creative Bioarray provides in vivo PK/PD services, using extensive expertise and models to support drug discovery and preclinical development of small molecules, peptides, nucleosides/nucleotides, and biologics.
Creative Bioarray provides comprehensive in vitro ADME services for drug discovery organizations. DDA platform’s in vitro ADME detection involves many forms to adapt to different stages of the drug discovery pipeline, and can provide flexible methods for ADME services. The experienced research team can also help design customized best strategies and programs to meet any drug discovery needs.
Creative Bioarray develops and executes fast, sensitive and robust bioanalysis methods for the extraction and quantification of drugs and metabolites in biological fluids and tissues to support preclinical research. Creative Bioarray provides cost-effective design and implementation for in vivo pharmacokinetic studies of various animal species, as well as rapid results turnaround to facilitate every stage of molecular development.
Besides, Creative Bioarray has deep expertise in the in vitro and in vivo analysis, identification and structural characterization of metabolites. Creative Bioarray utilizes advanced technology and software for accurate and reliable metabolite identification and structural characterization. In addition, synthetic chemistry services can be used to synthesize metabolites, reference standards, and internal standards to help method development and metabolite identification.
“Creative Bioarray has extensive industry experience in drug discovery and development, which can assist in timely research design, data interpretation, research planning and execution.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Our testing includes extensive physical and chemical testing, in vitro ADME testing, in vivo PK/PD and biological analysis, and toxicology testing.”
About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.